Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C.

EMBO Mol Med. 2018 Sep 17. pii: e9316. doi: 10.15252/emmm.201809316. [Epub ahead of print]

2.

Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects.

David OJ, Behrje R, Pal P, Hara H, Lates CD, Schmouder R.

Clin Pharmacol Drug Dev. 2018 Aug;7(6):575-586. doi: 10.1002/cpdd.459. Epub 2018 Apr 25.

3.

Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod.

David OJ, Berwick A, Pezous N, Lang M, Tiel-Wilck K, Ziemssen T, Li P, Hara H, Schmouder R.

Clin Pharmacol Drug Dev. 2018 Feb;7(2):217-221. doi: 10.1002/cpdd.424. Epub 2017 Dec 19.

4.

The selective metabotropic glutamate receptor 5 antagonist mavoglurant (AFQ056) reduces the incidence of reflux episodes in dogs and patients with moderate to severe gastroesophageal reflux disease.

Rouzade-Dominguez ML, Pezous N, David OJ, Tutuian R, Bruley des Varannes S, Tack J, Malfertheiner P, Allescher HD, Ufer M, Rühl A.

Neurogastroenterol Motil. 2017 Aug;29(8). doi: 10.1111/nmo.13058. Epub 2017 Mar 23.

PMID:
28337838
5.

Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study.

David OJ, Pryce M, Meiser K, Picard F, Emotte C, Kobalava Z, Moiseev V, Schmouder R.

Int J Clin Pharmacol Ther. 2015 Oct;53(10):847-54. doi: 10.5414/CP202356.

PMID:
26308173
6.

Effect of fingolimod (FTY720) on cerebral blood flow, platelet function and macular thickness in healthy volunteers.

Ocwieja M, Meiser K, David OJ, Valencia J, Wagner F, Schreiber SJ, Pleyer U, Ziemer S, Schmouder R.

Br J Clin Pharmacol. 2014 Dec;78(6):1354-65. doi: 10.1111/bcp.12454.

7.

Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma.

Boulton C, David OJ, Meiser K, Schmouder R.

Clin Pharmacol Drug Dev. 2013 Jan;2(1):2-10. doi: 10.1002/cpdd.4. Epub 2013 Mar 4.

PMID:
27121555
8.

Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.

David OJ, Ocwieja M, Meiser K, Emotte C, Jakab A, Wemer J, den Daas I, Schmouder R.

Int J Clin Pharmacol Ther. 2012 Aug;50(8):540-4. doi: 10.5414/CP201675.

PMID:
22735460
9.

Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study.

Boulton C, Meiser K, David OJ, Schmouder R.

J Clin Pharmacol. 2012 Dec;52(12):1879-90. doi: 10.1177/0091270011427908. Epub 2011 Dec 15.

PMID:
22174429
10.

Clinical pharmacokinetics of fingolimod.

David OJ, Kovarik JM, Schmouder RL.

Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000. Review.

PMID:
22149256
11.

Population pharmacokinetics of fingolimod phosphate in healthy participants.

Wu K, Mercier F, David OJ, Schmouder RL, Looby M.

J Clin Pharmacol. 2012 Jul;52(7):1054-68. doi: 10.1177/0091270011409229. Epub 2011 Nov 22.

PMID:
22110161
12.

Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers.

Schmouder R, Hariry S, David OJ.

Eur J Clin Pharmacol. 2012 Apr;68(4):355-62. doi: 10.1007/s00228-011-1146-9. Epub 2011 Nov 10.

PMID:
22071882
13.

Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor.

Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, Wu X, Pan S, Mickel L, Schuster C, Stary G, Jalili A, David OJ, Emotte C, Antunes AM, Rose K, Decker J, Carlson I, Gardner H, Stuetz A, Bertolino AP, Stingl G, De Rie MA.

J Invest Dermatol. 2011 Aug;131(8):1735-44. doi: 10.1038/jid.2011.48. Epub 2011 Mar 24.

14.

NHS Direct and older people.

David OJ.

Age Ageing. 2005 Sep;34(5):499-501. No abstract available.

PMID:
16107454
15.

Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation.

Monchaud C, Rousseau A, Leger F, David OJ, Debord J, Dantoine T, Marquet P.

Eur J Clin Pharmacol. 2003 Apr;58(12):813-20. Epub 2003 Mar 6.

PMID:
12698308
16.

Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.

Banner NR, David OJ, Leaver N, Davis J, Breen J, Johnston A, Yacoub MH.

Transpl Int. 2002 Dec;15(12):649-54. Epub 2002 Nov 22.

PMID:
12478413
17.
18.

Pharmacokinetic validation of neoral absorption profiling.

Johnston A, David OJ, Cooney GF.

Transplant Proc. 2000 May;32(3A Suppl):53S-56S. No abstract available.

PMID:
10814750
19.

Communication disturbances and hyperactive/conduct-disturbed behavior.

David OJ, Wintrob HL.

Psychiatry. 1989 Nov;52(4):379-92.

PMID:
2587676
20.

[Histological study of peri-implant tissues. Intraosseous implants in surgical chromium-cobalt molybdenum].

Fonseca MM, David OJ, Ferreyra FJ.

Rev Fac Odontol Univ Nac (Cordoba). 1988 Jan-Dec;16(1-2):27-36. Spanish. No abstract available.

PMID:
3274259
21.

[Presence of dentinal smear layer after surgical preparation of the molars].

Ulfohn R, David OJ, Rodrigo S, Visvisian C.

Rev Esp Endodoncia. 1985 Dec;3(3):97-105. Spanish. No abstract available.

PMID:
3869974
22.

Chelation therapy in children as treatment of sequelae in severe lead toxicity.

David OJ, Katz S, Arcoleo CG, Clark J.

Arch Environ Health. 1985 Mar-Apr;40(2):109-13.

PMID:
4004343
23.

The relationship of hyperactivity to moderately elevated lead levels.

David OJ, Hoffman SP, Clark J, Grad G, Sverd J.

Arch Environ Health. 1983 Nov-Dec;38(6):341-6.

PMID:
6667034
24.

Response to letter on lead levels article.

David OJ, Grad G, McGann B, Koltun A.

Am J Psychiatry. 1983 Apr;140(4):516. No abstract available.

PMID:
6837807
25.

Predicting psychiatric admission from an emergency room. Psychiatric, psychosocial, and methodological factors.

Friedman S, Margolis R, David OJ, Kesselman M.

J Nerv Ment Dis. 1983 Mar;171(3):155-8.

PMID:
6827253
26.

Mental retardation and "nontoxic" lead levels.

David OJ, Grad G, McGann BU, Koltun A.

Am J Psychiatry. 1982 Jun;139(6):806-9.

PMID:
7081497
27.

Blood lead stability.

David OJ, Wintrob HL, Arcoleo CG.

Arch Environ Health. 1982 May-Jun;37(3):147-50.

PMID:
7092331
28.

Childhood lead poisoning: a re-evaluation.

David OJ, Clark J, Hoffman S.

Arch Environ Health. 1979 Mar-Apr;34(2):106-11.

PMID:
434930
29.

Threshold levels and lead toxicity [proceedings].

David OJ, Hoffman S, Koltun A.

Psychopharmacol Bull. 1978 Jul;14(3):50-3. No abstract available.

PMID:
674536
30.

Lead and hyperactivity: lead levels among hyperactive children.

David OJ, Hoffman SP, Sverd J, Clark J.

J Abnorm Child Psychol. 1977 Dec;5(4):405-16.

PMID:
604381
31.

[Anatomy of the trigeminal nerve].

David OJ.

Rev Fac Odontol Univ Nac (Cordoba). 1977 Jul-Dec;9(2):95-121. Spanish. No abstract available.

PMID:
279049
32.

Blood-lead and mental retardation.

David OJ, Hoffman S.

Lancet. 1977 Apr 23;1(8017):906. No abstract available.

PMID:
67312
33.

Lead and hyperactivity. Behavioral response to chelation: a pilot study.

David OJ, Hoffman SP, Sverd J, Clark J, Voeller K.

Am J Psychiatry. 1976 Oct;133(10):1155-8.

PMID:
823826
34.

The role of lead in hyperactivity.

David OJ, Hoffman SP, Sverd J.

Psychopharmacol Bull. 1976 Apr;12(2):11-3. No abstract available.

PMID:
1257385
35.

Letter: Blood-lead levels, behaviour, and intelligence.

David OJ.

Lancet. 1974 May 4;1(7862):866. No abstract available.

PMID:
4132816
36.

Supplemental Content

Loading ...
Support Center